This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2023
  • /
  • 3
  • /
  • Phase III ECZTRA 6 and ECZTEND trials of Adbry in ...

Phase III ECZTRA 6 and ECZTEND trials of Adbry in atopic dermatitis reported at AAD 2023 Annual Meeting.- LEO Pharma

Read time: 1 mins
Published:18th Mar 2023

S. aureus is consistently found in the skin lesions of patients with AD and contributes to skin irritation and infections. A correlation between disease severity and S. aureus colonization has been demonstrated in clinical studies. At Week 16, 49% of patients receiving Adbry 150 mg (n=81) and 43% of patients receiving Adbry 300 mg (n=82) went from testing positive for S. aureus to negative in lesional skin, compared to the 14% receiving placebo (n=80). Similar reductions were seen in Adbry-treated patients with S. aureus positive non-lesional skin.

Additional data in adolescent patients from ECZTRA 6 demonstrated that 16 weeks of treatment with Adbry showed an improvement in skin gene expression from a lesional to a non-lesional skin profile. The improvement occurred in 29% (n=29) and 41% (n=27) of the differentially expressed genes in lesional skin in patients treated with Adbry (for the 150 mg and 300 mg groups, respectively), compared to a 4% improvement in the placebo group (n=27). At Week 8, Adbry 150 mg and 300 mg led to 35% 9 (n=29) and 33% (n=27) improvement respectively in gene expression, compared to a 10% (n=27) improvement with placebo.

All participants who completed the ECZTRA 6 trial were eligible to enter the ongoing ECZTEND open-label extension trial. An interim analysis of this trial evaluated the long-term safety and efficacy of Adbry among adolescents from ECZTRA 6 who moved into ECZTEND. The results of the analysis showed that the long-term safety profile of Adbry for up to three years in the adolescent population (n=127) was consistent with that of the ECZTEND adult population, with no new safety issues identified. Additionally, approximately eight out of 10 patients had at least a 75% improvement in the extent and severity of AD (EASI-75) at two years of treatment with Adtralza (84.4% AO (n=109), 78.7% mNRI (n=127), 78.7% LOCF (n=127). The data was presented at the American Academy of Dermatology (AAD) 2023 Annual Meeting. The use of Adbry in adolescent patients aged 12-17 is currently under clinical investigation and the safety and efficacy have not been fully evaluated by the U.S. FDA.

Condition: Atopic Dermatitis (Eczema)
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights